About Provention BioProvention Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease. Our "predict and prevent" therapeutic model is focused on developing drugs that intervene before the targeted disease begins, re-appears or progresses. This innovative approach offers the potential to reduce the high morbidity, mortality, patient suffering, and escalating costs of chronic autoimmune and inflammatory diseases, such as type 1 diabetes (T1D), Crohn's disease, ulcerative colitis, and emerging viruses.
Co-Founder & CEO: Ashleigh Palmer
Scientific Co-Founder: Francisco Leon, M.D., Ph.D.
45 articles with Provention Bio
9/27/2019Biotech and pharma companies strengthen their leadership teams and boards of directors with this week's appointments.
T1D Fund Executive Chairman and Former Bain Capital Managing Director Brings Extensive Financial Expertise and Deep Knowledge of Therapeutics Landscape
Provention Bio, Inc. announced that management will present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2, 2019, at 4:45 pm E.T. The conference is being held at the InterContinental New York Barclay Hotel, New York, NY.
Provention Bio Reiterates Regulatory Strategy for PRV-031 and Announces Completion of Follow-on Financing
Provention Bio, Inc., (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reiterated its regulatory strategy regarding PRV-031 (teplizumab) for the prevention or delay of clinical type 1 diabetes (T1D) in individuals at-risk of developing the disease
Provention Bio, Inc. announced the pricing of its previously announced underwritten registered public offering of 5,000,000 shares of its common stock, offered at a public offering price of $8.00 per share for expected gross proceeds of $40.0 million, before deducting underwriting discounts and other estimated offering expenses.
Provention Bio, Inc. announced that it has commenced an underwritten public offering of shares of its common stock.
Provention Bio, Inc. announced that management will present at the H.C. Wainwright 21st Annual Global Investment Conference on Tuesday, September 10, 2019, at 8:45 am E.T. The conference is being held at the Lotte New York Palace, New York, NY.
8/23/2019Biopharma companies strengthen their senior leadership teams and boards of directors with this week's appointments.
Appoints Dr. Sherron Kell as SVP of Clinical Development and Program Lead for PRV-031 (Teplizumab)
Bispecific Diabody Designed to Intercept B-Cell Mediated Autoimmune Diseases
PRV-031 Granted Breakthrough Therapy Designation for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals
Provention Bio Announces Breakthrough Therapy Designation for Teplizumab (PRV-031) for the Prevention or Delay of Clinical Type 1 Diabetes in At-Risk Individuals
BTD is an FDA program designed to expedite the development and review of therapeutic candidates intended to treat serious or life-threatening diseases.
Tiziana Life Science reports Independent Third Party Article in New England Journal of Medicine on Intravenous Treatment with a Humanized Anti-CD3 mAb showing delays in progression of Type 1 Diabetes
Independent third party Phase 2 results show Teplizumab, a mouse derived humanized anti-CD3 monoclonal antibody (mAb) significantly slowed progression of Type 1 diabetes in high risk population
6/17/2019Last week there were quite a few clinical trials whose data were presented. Many were at the American Diabetes Association 79th Scientific Sessions, while others were presented at separate meetings or independently. Here’s a look.
Provention Bio, Inc. announced that it has terminated the public offering of common stock previously announced on June 10, 2019.
Provention Bio, Inc. announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a registered underwritten public offering of 5,500,000 shares of its common stock.
Trial data showed a two-week course delayed the onset of diabetes by as much as two years in clinical patients.
A Single Course of Provention's PRV-031 (Teplizumab) Delays Type 1 Diabetes Onset in High-Risk Individuals by at Least Two Years
Results from the NIH-Sponsored "At-Risk" Study Published in The New England Journal of Medicine and Presented at the American Diabetes Association Annual Meeting
PROTECT Pivotal Phase 3 Clinical Study Initiated in Patients with Recent Onset Type 1 Diabetes Top line Data Results for PRINCE and At-Risk Clinical Trials Expected in 2019
Provention Bio Announces Top-Line Results from its Phase 1b PULSE Clinical Trial of PRV-300 in Patients with Moderate-to-Severe Ulcerative Colitis
Top-line results from its Phase 1b PULSE study which evaluated PRV-300, an anti-TLR3 monoclonal antibody, in patients with active, moderate-to-severe ulcerative colitis